ERVEBO 72000000 PFU — DIN 02532603
RVSV [DELTA] G-ZEBOV-GP, LIVE ATTENUATED : 72000000 PFU · MERCK CANADA INC · SOLUTION · wholesale supply in Canada
Health Canada status: APPROVED
What is ERVEBO?
ERVEBO 72000000 PFU contains RVSV [DELTA] G-ZEBOV-GP, LIVE ATTENUATED : 72000000 PFU. It is listed in the Health Canada Drug Product Database under DIN 02532603, held by MERCK CANADA INC, supplied as SOLUTION for INTRAMUSCULAR administration. Health Canada currently lists it as approved, status dated 09-Nov-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
What is ERVEBO used for?
Active immunization of individuals 18 years of age or older to protect against Ebola Virus Disease (EVD) caused by Zaire Ebola virus.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 72000000 PFU |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAMUSCULAR |
| Pack configuration (monograph) | 1 mL single-dose vial (type I glass) with a chlorobutyl stopper and flip-off plastic cap with aluminium seal. Available in pack sizes of 10 vials. |
| Storage | Not explicitly detailed in the provided text (section 11 header present but content cut off), though typically requires ultra-low temperature storage. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Ebola Vaccines |
|---|---|
| ATC code | J07BX02 |
| AHFS class | 80:12.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02532603 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2532603 |
| Brand name | ERVEBO |
| Generic / active ingredient | RVSV [DELTA] G-ZEBOV-GP, LIVE ATTENUATED : 72000000 PFU |
| Market authorization holder | MERCK CANADA INC |
| Health Canada schedule | Schedule D |
| ATC code | J07BX02 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J07BX |
| Current status | APPROVED |
| Status date | 09-Nov-2022 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Single 1 mL dose administered intramuscularly (IM) for primary immunization. Preferred site is the deltoid or higher anterolateral thigh. Do not inject intravascularly.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to the vaccine, any ingredient in the formulation (including rice protein), or component of the container.
Warnings and precautions
Does not eliminate need for PPE. Risk of transmission of vaccine virus to high-risk individuals for 6 weeks. Potential for arthralgia/arthritis and rash. Do not donate blood for 6 weeks.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
2 · Same class — other molecules in ATC J07BX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Respiratory Syncytial Virus Vaccine | ABRYSVO · AREXVY · MRESVIA | 3 | 3 | Yes |
| Chikungunya Vaccines | IXCHIQ | 1 | 1 | Yes |
| Other Viral Vaccines | ADENOVIRUS VACCINE LIVE ORAL TYPE 4 · ADENOVIRUS VACCINE LIVE ORAL TYPE 7 · SMALLPOX VACCINE (GLYCERINATED) | 3 | 0 | Not in Canada |
| Ebola Vaccines | ERVEBO | 1 | 0 | Not in Canada |
| Smallpox And Monkeypox Vaccines | SMALLPOX VACCINE (DRIED) | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J07B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J07BB | Influenza, Inactivated, Split Virus Or Surface Antigen · Influenza, Inactivated, Whole Virus · Influenza, Live Attenuated | 41 | 10 |
| J07BC | Combinations · Hepatitis A, Inactivated, Whole Virus · Hepatitis B, Purified Antigen | 19 | 9 |
| J07BN | Covid-19, Protein Subunit · Covid-19, Rna-Based Vaccine · Covid-19, Viral Vector, Non-Replicating | 28 | 5 |
| J07BD | Measles, Combin. With Mumps And Rubella, Live Attenuated · Measles, Combinations With Mumps, Rubella And Varicella, Live Attenuated · Morbilli, Comb. With Rubella, Live Attenuated · Morbilli, Live Attenuated | 8 | 4 |
| J07BK | Varicella Zoster Vaccines · Varicella, Live Attenuated · Zoster, Live Attenuated | 7 | 3 |
| J07BG | Rabies, Inactivated, Whole Virus | 3 | 2 |
| J07BH | Rota Virus, Live Attenuated · Rota Virus, Pentavalent, Live, Reassorted | 2 | 2 |
| J07BM | Papillomavirus (Human Types 16,18) · Papillomavirus (Human Types 6,11,16,18,31,33,45,52,58) · Papillomavirus (Human Types 6,11,16,18) | 3 | 2 |
4 · Fixed-dose combinations with Canadian supply
| Product | Active ingredients | Holder | Status | DIN |
|---|---|---|---|---|
| AVAXIM | HEPATITIS A VIRUS, INACTIVATED : 160 UNIT / 0.5 ML | SANOFI PASTEUR LIMITED | MARKETED | 02237792 |
| COMIRNATY | *SARSCOV2 S-PROTEIN MRNA, 5'[M27,3'-OGPPP(M12'-O)APG], 3'POLYA+LINKER : 30 MCG / 0.3 ML | BIONTECH MANUFACTURING GMBH | MARKETED | 02552035 |
| HAVRIX 1440 | HEPATITIS A VIRUS, INACTIVATED : 1440 UNIT | GLAXOSMITHKLINE INC | MARKETED | 02187078 |
| HAVRIX 720 JUNIOR | HEPATITIS A VIRUS, INACTIVATED : 720 UNIT / 0.5 ML | GLAXOSMITHKLINE INC | MARKETED | 02231056 |
| MRESVIA | *RSV F-PROTEIN MRNA, 5'(M7G-5'-PPP-5'-GM), 3'POLYA : 50 MCG / 0.5 ML | MODERNA BIOPHARMA CANADA CORPORATION | MARKETED | 02552914 |
| ROTARIX | ROTAVIRUS VACCINE (RIX4414 STRAIN), LIVE, ORAL, ATTENUATED (HUMAN) : 1000000 CCID50 / 1.5 ML | GLAXOSMITHKLINE INC | MARKETED | 02300591 |
| SPIKEVAX | *SARSCOV2 S-PROTEIN MRNA, 5'(M7G-5'-PPP-5'-GM), 3'POLYA : 0.1 MG | MODERNA BIOPHARMA CANADA CORPORATION | MARKETED | 02541270 |
| TWINRIX | HEPATITIS B SURFACE ANTIGEN (RECOMBINANT) : 20 MCG / 1 ML HEPATITIS A VIRUS, INACTIVATED : 720 UNIT / 1 ML | GLAXOSMITHKLINE INC | MARKETED | 02230578 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
This product is approved by Health Canada but not yet marketed in Canada, so there is no Canadian supply to draw on today. Nexara can tell you whether it has been launched, and can look at supply from other markets where a Canadian pack is not required or where importation is permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.